Jeppson Wealth Management’s Cidara Therapeutics CDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-6,155
Closed -$589K 227
2025
Q3
$589K Hold
6,155
0.19% 107
2025
Q2
$300K Buy
+6,155
New +$148K 0.1% 169
2024
Q2
Sell
-7,433
Closed -$137K 207
2024
Q1
$137K Buy
7,433
+310
+4% +$4.45K 0.05% 201
2023
Q4
$113K Buy
7,123
+245
+4% +$3.94K 0.05% 197
2023
Q3
$130K Buy
6,878
+122
+2% +$2.4K 0.06% 178
2023
Q2
$153K Sell
6,756
-97
-1% -$2.28K 0.07% 187
2023
Q1
$174K Sell
6,853
-1,178
-15% -$33.4K 0.08% 189
2022
Q4
$121K Sell
8,031
-678
-8% -$8.09K 0.05% 201
2022
Q3
$109K Sell
8,709
-345
-4% -$4.76K 0.05% 189
2022
Q2
$88K Buy
9,054
+1,861
+26% +$23K 0.04% 189
2022
Q1
$119K Buy
7,193
+1,667
+30% +$28.3K 0.06% 169
2021
Q4
$140K Buy
5,526
+2,521
+84% +$78.5K 0.07% 156
2021
Q3
$134K Buy
3,005
+400
+15% +$15.2K 0.07% 153
2021
Q2
$105K Buy
2,605
+227
+10% +$9.61K 0.06% 149
2021
Q1
$126K Sell
2,378
-235
-9% -$11.6K 0.07% 138
2020
Q4
$105K Buy
2,613
+1,015
+64% +$50.5K 0.07% 136
2020
Q3
$91K Buy
+1,598
New +$113K 0.07% 176

Other funds holding CDTX

Jeppson Wealth Management's CDTX Position: Q4 2025 in Review

Jeppson Wealth Management sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 6,155 shares — an estimated $589K sold.

Jeppson Wealth Management first reported a position in CDTX in Q3 2020 and held it in 17 quarters. The position peaked at $589K in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

  • Jeppson Wealth Management reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jeppson Wealth Management sold 6,155 Cidara Therapeutics shares in Q4 2025, an estimated $589K.
  • Jeppson Wealth Management first reported a position in Cidara Therapeutics in Q3 2020 and held it in 17 quarters.
  • Jeppson Wealth Management's Cidara Therapeutics position peaked at $589K in Q3 2025.
  • 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Jeppson Wealth Management's 13F filing for Q4 2025, filed 27 Jan 2026.